AcSDKP EIA Kit

N-Acetyl Ser-Asp-Lys-Pro (AcSDKP) is a tetrapeptide growth regulatory hormone which inhibits the proliferation of hematopoietic stem cells. The dipeptidase Angiotensin Converting Enzyme (ACE) actively metabolizes circulating AcSDKP, giving it a brief plasma half life of 4 to 5 minutes. ACE inhibition is a major therapeutic end point in the treatment of hypertension management. A further consequence of ACE inhibition is the accumulation of AcSDKP in the plasma and the urine. This accumulation may have physiological effects, which are manifested as the anemia of chronic ACE inhibitor toxicity. More commonly, plasma and urine AcSDKP levels can be used as a biomarker of ACE inhibition and an index of patient compliance with therapy. Measurement of AcSDKP in human urine or plasma can be readily accomplished by enzyme immunoassay. [Bertin Catalog No. A05881]

[1] M LENFANT. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86 3: 779-782. DOI: 10.1073/pnas.86.3.779
[2] M AZIZI. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.[J]. Hypertension, 1997, 30 5: 1015-1019. DOI: 10.1161/01.hyp.30.5.1015
[3] M AZIZI. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.[J]. Hypertension, 1999, 33 3: 879-886. DOI: 10.1161/01.hyp.33.3.879
[4] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[5] PHILIPPE PRADELLES . Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay[J]. Biochemical and biophysical research communications, 1990, 170 3: Pages 986-993. DOI: 10.1016/0006-291x(90)90489-a